表面活性剂及其在肺部感染的病理生物学中的作用。
Surfactant and its role in the pathobiology of pulmonary infection.
机构信息
Department of Medicine, Acute Lung Injury Center of Excellence, Pittsburgh, PA 15213, USA.
出版信息
Microbes Infect. 2012 Jan;14(1):17-25. doi: 10.1016/j.micinf.2011.08.019. Epub 2011 Sep 10.
Abstract
Pulmonary surfactant is a complex surface-active substance comprised of key phospholipids and proteins that has many essential functions. Surfactant's unique composition is integrally related to its surface-active properties, its critical role in host defense, and emerging immunomodulatory activities ascribed to surfactant lipids. Together these effector functions provide for lung stability and protection from a barrage of potentially virulent infectious pathogens.
摘要
肺表面活性剂是一种复杂的表面活性物质，由关键的磷脂和蛋白质组成，具有许多重要的功能。表面活性剂的独特组成与其表面活性特性、在宿主防御中的关键作用以及归因于表面活性剂脂质的新兴免疫调节活性密切相关。这些效应功能共同为肺部提供稳定性，并防止一系列潜在的致命性传染性病原体的侵害。
相似文献
1
Surfactant and its role in the pathobiology of pulmonary infection.表面活性剂及其在肺部感染的病理生物学中的作用。
Microbes Infect. 2012 Jan;14(1):17-25. doi: 10.1016/j.micinf.2011.08.019. Epub 2011 Sep 10.
2
The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.表面活性剂在肺部疾病及宿主抵御肺部感染中的作用
Ann Am Thorac Soc. 2015 May;12(5):765-74. doi: 10.1513/AnnalsATS.201411-507FR.
3
Pulmonary surfactant: an immunological perspective.肺表面活性物质：免疫学视角
Cell Physiol Biochem. 2010;25(1):13-26. doi: 10.1159/000272047. Epub 2009 Dec 22.
4
[Newly discovered association between lung disease and surfactant proteins].[肺部疾病与表面活性物质蛋白之间新发现的关联]
Lakartidningen. 2002 Mar 14;99(11):1191-4.
5
Pulmonary surfactant metabolism in the alveolar airspace: Biogenesis, extracellular conversions, recycling.肺泡气腔内的肺表面活性物质代谢：生物合成、细胞外转化、再循环
Ann Anat. 2017 Jan;209:78-92. doi: 10.1016/j.aanat.2016.09.008. Epub 2016 Oct 20.
6
An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.新生儿肺表面活性物质概述：遗传学、代谢以及表面活性物质在健康与疾病中的作用
Mol Genet Metab. 2009 Jun;97(2):95-101. doi: 10.1016/j.ymgme.2009.01.015. Epub 2009 Feb 4.
7
Pulmonary surfactant: a front line of lung host defense.肺表面活性物质：肺部宿主防御的前沿防线。
J Clin Invest. 2003 May;111(10):1453-5. doi: 10.1172/JCI18650.
8
Effect of triiodothyronine augmentation on rat lung surfactant phospholipids during sepsis.
J Appl Physiol (1985). 1997 Jun;82(6):2020-7. doi: 10.1152/jappl.1997.82.6.2020.
9
Recent progress on surfactant protein A: cellular function in lung and kidney disease development.表面活性蛋白 A 的最新进展：肺和肾脏疾病发展中的细胞功能。
Am J Physiol Cell Physiol. 2020 Aug 1;319(2):C316-C320. doi: 10.1152/ajpcell.00195.2020. Epub 2020 Jul 8.
10
Potential role of surfactant proteins A and D in innate lung defense against pathogens.表面活性蛋白A和D在肺部先天性抵御病原体中的潜在作用
Biol Neonate. 1995;67 Suppl 1:2-17. doi: 10.1159/000244202.
引用本文的文献
1
Prolonged in vitro anti-bacterial, anti-inflammatory, and surfactant-promoting effects of volatile anesthetics.挥发性麻醉剂的体外抗菌、抗炎和促进表面活性剂作用的延长效应。
BMC Pulm Med. 2025 Sep 9;25(1):425. doi: 10.1186/s12890-025-03849-w.
2
Is Altered Surfactant Protein Gene Expression in Peripheral Blood Associated with COVID-19 Disease Severity?外周血中表面活性蛋白基因表达的改变与新冠病毒疾病严重程度相关吗？
Diagnostics (Basel). 2025 Jul 2;15(13):1690. doi: 10.3390/diagnostics15131690.
3
Genetic prediction of immune cells, inflammatory proteins, and metabolite-mediated association between gut microbiota and COPD: a Mendelian randomization study.免疫细胞、炎症蛋白以及肠道微生物群与慢性阻塞性肺疾病之间代谢物介导关联的遗传预测：一项孟德尔随机化研究
Sci Rep. 2025 Jul 1;15(1):21633. doi: 10.1038/s41598-025-05290-9.
4
A nomogram for predicting neonatal acute respiratory distress syndrome in patients with neonatal pneumonia after 34 weeks of gestation.一种用于预测孕34周后新生儿肺炎患者发生新生儿急性呼吸窘迫综合征的列线图。
Front Pediatr. 2025 Jan 9;12:1451466. doi: 10.3389/fped.2024.1451466. eCollection 2024.
5
Association Between Albumin Levels and Neonatal Acute Respiratory Distress Syndrome in Newborn Pneumoniae.新生儿肺炎中白蛋白水平与新生儿急性呼吸窘迫综合征的关系
J Inflamm Res. 2024 Nov 28;17:10015-10026. doi: 10.2147/JIR.S492404. eCollection 2024.
6
[Advances on physiology and pathology of subpopulations of macrophages in the lung tissue].[肺组织中巨噬细胞亚群的生理与病理研究进展]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Oct 25;53(5):650-658. doi: 10.3724/zdxbyxb-2024-0129.
7
Towards personalized therapies for genetic disorders of surfactant dysfunction.面向表面活性剂功能障碍遗传疾病的个体化治疗。
Semin Fetal Neonatal Med. 2023 Dec;28(6):101500. doi: 10.1016/j.siny.2023.101500. Epub 2023 Nov 22.
8
An Analysis of Targeted Serum Lipidomics in Patients with Pneumoconiosis - China, 2022.2022年中国尘肺病患者靶向血清脂质组学分析
China CDC Wkly. 2023 Sep 22;5(38):849-855. doi: 10.46234/ccdcw2023.161.
9
Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.表面活性物质替代疗法作为 COVID-19 的有前途的治疗方法：更新的叙述性综述。
Biosci Rep. 2023 Aug 31;43(8). doi: 10.1042/BSR20230504.
10
Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality.COVID-19 患者死后肺组织的分子特征表明存在不同的死亡驱动轨迹。
Dis Model Mech. 2022 May 1;15(5). doi: 10.1242/dmm.049572. Epub 2022 Jun 6.
本文引用的文献
1
The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding.大流行性流感病毒血凝素诱导下呼吸道病理学的能力与表面活性剂蛋白 D 结合减少有关。
Virology. 2011 Apr 10;412(2):426-34. doi: 10.1016/j.virol.2011.01.029. Epub 2011 Feb 18.
2
The Pseudomonas aeruginosa flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorum-sensing.铜绿假单胞菌鞭毛通过群体感应影响外蛋白酶的产生从而赋予其对肺表面活性剂蛋白 A 的抗性。
Mol Microbiol. 2011 Mar;79(5):1220-35. doi: 10.1111/j.1365-2958.2010.07516.x. Epub 2011 Jan 6.
3
Surface-bound myeloperoxidase is a ligand for recognition of late apoptotic neutrophils by human lung surfactant proteins A and D.表面结合的髓过氧化物酶是人肺表面活性蛋白 A 和 D 识别晚期凋亡中性粒细胞的配体。
Protein Cell. 2010 Jun;1(6):563-72. doi: 10.1007/s13238-010-0076-0. Epub 2010 Jul 7.
4
Pulmonary surfactant in respiratory syncytial virus bronchiolitis: the role in pathogenesis and clinical implications.呼吸道合胞病毒细支气管炎中的肺表面活性物质：在发病机制中的作用及临床意义
Pediatr Pulmonol. 2011 May;46(5):415-20. doi: 10.1002/ppul.21395. Epub 2010 Dec 30.
5
Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis.血清 SP-D 水平作为呼吸道合胞病毒细支气管炎肺损伤的生物标志物。
Pediatr Pulmonol. 2011 Jan;46(1):18-22. doi: 10.1002/ppul.21270. Epub 2010 Dec 9.
6
Phospholipid packing and hydration in pulmonary surfactant membranes and films as sensed by LAURDAN.通过LAURDAN检测肺表面活性物质膜和薄膜中的磷脂堆积与水合作用。
Biochim Biophys Acta. 2011 Mar;1808(3):696-705. doi: 10.1016/j.bbamem.2010.11.019. Epub 2010 Nov 30.
7
Surfactant protein A (SP-A)-mediated clearance of Staphylococcus aureus involves binding of SP-A to the staphylococcal adhesin eap and the macrophage receptors SP-A receptor 210 and scavenger receptor class A.表面活性蛋白 A (SP-A) 介导的金黄色葡萄球菌清除作用涉及 SP-A 与金黄色葡萄球菌黏附素 eap 以及巨噬细胞受体 SP-A 受体 210 和清道夫受体 A 结合。
J Biol Chem. 2011 Feb 11;286(6):4854-70. doi: 10.1074/jbc.M110.125567. Epub 2010 Dec 1.
8
Lung surfactant DPPG phospholipid inhibits vaccinia virus infection.肺表面活性剂二棕榈酰磷脂酰甘油抑制牛痘病毒感染。
Antiviral Res. 2011 Jan;89(1):89-97. doi: 10.1016/j.antiviral.2010.11.009. Epub 2010 Nov 21.
9
Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films.SP-B 和 SP-C 蛋白在肺表面活性物质膜表面行为和机械稳定性中的联合和独立作用。
Biophys J. 2010 Nov 17;99(10):3290-9. doi: 10.1016/j.bpj.2010.09.039.
10
Crystallographic complexes of surfactant protein A and carbohydrates reveal ligand-induced conformational change.表面活性剂蛋白 A 与碳水化合物的晶体复合物揭示配体诱导的构象变化。
J Biol Chem. 2011 Jan 7;286(1):757-65. doi: 10.1074/jbc.M110.175265. Epub 2010 Nov 3.
Zotero 插件